Heterocyclic CB1 receptor antagonists

Details Heterocyclic CB1 receptor antagonists Heterocyclic CB1 receptor antagonists

2007-05-22

2007-05-22

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S148000

Reexamination Certificate

active

11266445

ABSTRACT:
The present invention relates to compounds of formulawherein R1and R2are each independently hydrogen or halogen. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1receptors.

REFERENCES:
patent: 3940418 (1976-02-01), Hamilton
patent: 5462960 (1995-10-01), Barth et al.
patent: 5596106 (1997-01-01), Cullinan et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 6355631 (2002-03-01), Achard et al.
patent: 6479479 (2002-11-01), Achard et al.
patent: 6518264 (2003-02-01), Achard et al.
patent: 6566356 (2003-05-01), Achard et al.
patent: 6734176 (2004-05-01), Achard et al.
patent: 6858603 (2005-02-01), Achard et al.
patent: 6872717 (2005-03-01), Achard et al.
patent: 2001/0027193 (2001-10-01), Achard et al.
patent: 2002/0019383 (2002-02-01), Achard et al.
patent: 2002/0035102 (2002-03-01), Achard et al.
patent: 2003/0055033 (2003-03-01), Achard et al.
patent: 2003/0119810 (2003-06-01), Achard et al.
patent: 2003/0162808 (2003-08-01), Achard et al.
patent: 2004/0157823 (2004-08-01), Achard et al.
patent: 2004/0235816 (2004-11-01), Achard et al.
patent: 2005/0130953 (2005-06-01), Achard et al.
patent: 576357 (1993-12-01), None
patent: 656354 (1995-06-01), None
patent: 658546 (1995-06-01), None
patent: 2783246 (2000-03-01), None
patent: 2805810 (2001-09-01), None
patent: 2805817 (2001-09-01), None
patent: 2805818 (2001-09-01), None
patent: WO9602248 (1996-02-01), None
patent: WO9719063 (1997-05-01), None
patent: WO0015609 (2000-03-01), None
patent: WO0046209 (2000-08-01), None
patent: WO0132663 (2001-05-01), None
patent: WO0164632 (2001-09-01), None
patent: WO0164633 (2001-09-01), None
patent: WO0164634 (2001-09-01), None
patent: WO0170700 (2001-09-01), None
patent: WO0228346 (2002-04-01), None
patent: WO02076949 (2002-10-01), None
patent: WO03020217 (2003-03-01), None
patent: WO0335005 (2003-05-01), None
patent: WO0337332 (2003-05-01), None
patent: WO03040107 (2003-05-01), None
patent: WO03051850 (2003-06-01), None
patent: WO03063781 (2003-08-01), None
patent: WO03077847 (2003-09-01), None
patent: WO03078413 (2003-09-01), None
patent: WO03082190 (2003-10-01), None
patent: WO03082833 (2003-10-01), None
patent: WO03084930 (2003-10-01), None
patent: WO03084943 (2003-10-01), None
patent: WO03086288 (2003-10-01), None
patent: WO03087037 (2003-10-01), None
patent: WO 2004/013120 (2004-02-01), None
patent: WO 2005/075450 (2005-08-01), None
Dietz et al, May 19, 2005, N Engl J Med, 352, 2100-2109.
R. Mechoulam (Ed.)in “Cannabinoids as therapeutic Agents”, 1986, pp. 1-20, CRC Press.
R. G. Pertwee, Pharmaceut. Sci. 3 (11) (1997) 539-545, E. M.
Williamson, F. J. Evans, Drugs 60 (6) (2000) 1303-1314.
R.G. Pertwee, Curr. Med. Chem., 6 (8) (1999) 635-664.
W.A. Devane, et al., Science 258 (1992) 1946-9.
V. Di Marzo, et al., Trends in Neuroscience 21 (12) (1998) 521-8.
A. C. Porter, C.C. Felder, Pharmacol. Ther., 90 (1) (2001) 45-60.
C.M. Williams, T.C. Kirkham, Psychopharmacology 143 (3) (1999) 315-317.
C. C. Felder, et al., Proc. Natl. Acad. Sci. U. S. A. 90 (16) (1993) 7656-60).
G. Colombo, et al., G. L. Gessa, Life Sci. 63 (8) (1998) L113-PL117.
V. Di Marzo, et al., Nature 410 (6830) 822-825.
A. I. Idris, et al., Nature Medicine 11 (7) (2005), 774-779.
F. Barth, et al., “Cannabinoid antagonists: From research tools to potential new drugs.” Abstracts of Papers, 222nd ACS National Meetings, Chicago, IL, United States, Aug. 26-30, 2001.
AAI; M. Pacheco, S. R. Childers, R. Arnold, F. Casiano, S. J. Ward, J. Pharmacol. Exp. Ther. 257 (1) (1991) 170-183.
F. M. Casiano, et al., NIDA Res. Monogr. 105 (1991) 295-6.
K. Hosohata, et al., Life Sci. 61 (1997) 115-118.
R. Pertwee, et al., Life Sci. 56 (23-24) (1995) 1949-55.
C. C. Felder, et al., J. Pharmacol. Exp. Ther. 284 (1) (1998) 291-7.
M. Kanyonyo, et al., Bioorg. Med. Chem. Lett. 9 (15) (1999) 2233-2236.
F. Ooms, et al., D. M. Lambert, J. Med. Chem. 45 (9) (2002) 1748-1756.
J.M. Mussinu et al., Bioorg.Med.Chem. 2003,11,251; S. Ruiu et al., J.Pharm.Expt.Ther., 2003,306,363.
G. Tarzia et al., Bioorg.Med.Chem. 2003,11,3965.

Affiliated with

Also associated with

Rating

Heterocyclic CB1 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclic CB1 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic CB1 receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3762396